Gilead entra in fase I/II con l’inibitore dell’integrase GS-9137

E’ iniziato l’arruolamento dello studio di fase I/II dell’inibitore dell’integrase GS-9137 per il trattamento dell’HIV. Il farmaco è targato Gilead Sciences. Lo studio valuterà la tollerabilità, la sicurezza e l’attività antivirale in persone HIV-positive.Questo il comunicato stampa dell’azienda:

GS 9137 is a novel HIV integrase inhibitor discovered by Japan Tobacco, Inc
(JT) and licensed to Gilead in March 2005. The license granted Gilead exclusive
rights to develop and commercialize GS 9137 in all countries of the world,
excluding Japan where JT will retain rights. GS 9137 has been previously
evaluated in a Phase I study in Japan to assess pharmacokinetics and safety in
healthy volunteers.

“The initiation of this trial underscores Gilead’s ongoing commitment to HIV
and efforts to advance novel compounds with the potential to address unmet
medical needs of people living with HIV,” said Norbert Bischofberger, PhD,
Executive Vice President, Research and Development, Gilead Sciences. “HIV continues
to be a major focus for Gilead, and integrase inhibitors represent a promising
novel class of agents with the potential to inhibit HIV replication,
particularly for patients whose HIV has developed resistance to other agents.”

As an investigational compound, GS 9137 has not yet been determined safe or
efficacious in humans for its ultimate intended use.